Advanced search×
×

Current Diabetes Reports

Print ISSN
1534-4827
Electronic ISSN
1539-0829
Impact factor
2.21
Publisher
springer
URL
http://www.springerlink.com/content/1539-0829/
Usage rank
3748
Article count
1121
Free count
22
Free percentage
0.0196253
PDFs via platforms
Metapress, Gale, and Springer

  1. Beyond HbA1c and glucose: the role of nontraditional glycemic markers in diabetes diagnosis, prognosis, and management.

    Current Diabetes Reports 14(11):548 (2014) PMID 25249070

    Fasting glucose and hemoglobin A1c (HbA1c) are the standard measures for diagnosis and monitoring of diabetes. There has been recent interest in nontraditional markers of hyperglycemia, including fructosamine, glycated albumin, and 1,5-anhydroglucitol (1,5-AG), as alternatives or adjuncts to standar...
  2. Risks and benefits of statin use in young people with type 1 diabetes.

    Current Diabetes Reports 14(7):499 (2014) PMID 24796934

    We will summarize the risks and benefits of statin use in young people with T1D....
  3. Risk vs benefit in diabetes pharmacotherapy: a rational approach to choosing pharmacotherapy in type 2 diabetes.

    Current Diabetes Reports 13(3):319 (2013) PMID 23512666

    We review the commonly prescribed pharmacotherapy options with attention to recently published information and provide a rational approach to choice of therapy....
  4. Novel targets against retinal angiogenesis in diabetic retinopathy.

    Current Diabetes Reports 12(4):355 (2012) PMID 22638940

    Proliferative diabetic retinopathy (PDR), characterized by pathologic retinal angiogenesis, is a major cause of blindness in the USA and globally. Treatments targeting vascular endothelial growth factor (VEGF) have emerged as a beneficial part of the therapeutic armamentarium for this condition, hig...
  5. Dual renin-angiotensin-aldosterone system blockade for diabetic kidney disease.

    Current Diabetes Reports 10(4):297 (2010) PMID 20532701 PMCID PMC3044643

    Blockade of the renin-angiotensin-aldosterone system (RAAS) prevents the development and progression of diabetic kidney disease (DKD). It is controversial whether the simultaneous use of two RAAS inhibitors (ie, dual RAAS blockade) further improves renal outcomes. This review examines the scientific...
  6. Current concepts about chromium supplementation in type 2 diabetes and insulin resistance.

    Current Diabetes Reports 10(2):145 (2010) PMID 20425574

  7. Best strategies for hypertension management in type 2 diabetes and obesity.

    Current Diabetes Reports 10(2):139 (2010) PMID 20425573

  8. The Eurodiab study: what has this taught us about diabetic peripheral neuropathy?

    Current Diabetes Reports 9(6):432 (2009) PMID 19954687

    Apart from tight blood glucose control, no other treatments have been shown to retard the progression of diabetic peripheral neuropathy (DPN). Therefore, identifying potential risk factors for DPN is important, particularly if they are modifiable. The Eurodiab baseline DPN study found a prevalence o...
  9. Aldosterone and diabetic kidney disease.

    Current Diabetes Reports 9(6):453 (2009) PMID 19954691

    Aldosterone plays an important role in salt and water homeostasis and blood pressure control through the classical mineralocorticoid receptor. However, recent findings of the mineralocorticoid receptor in nonepithelial tissues suggest that aldosterone may have additional functions. Significant evide...
  10. Treatment of hypertension in metabolic syndrome: implications of recent clinical trials.

    Current Diabetes Reports 9(3):229 (2009) PMID 19490825

    Metabolic syndrome represents a constellation of hypertension, abdominal obesity, impaired fasting glucose, and dyslipidemia, and it has been shown to be a risk factor for cardiovascular disease. The components of metabolic syndrome are rapidly emerging as epidemics of the twenty-first century, and...